CD5: A safeguard against autoimmunity and a shield for cancer cells

Autoimmunity Reviews

Volumn 8, Issue 4, 2009, Pages 349-353

  Dalloul, Ali ^a  

^a CHU NANCY BRABOIS   (France)

Author keywords

Autoimmunity; B cell receptor; CD5; Interleukin 10; Lymphocyte tumour interactions; T cell receptor

Indexed keywords

ASCOMYCIN; B LYMPHOCYTE RECEPTOR; CD5 ANTIGEN; CYCLOSPORIN A; INTERLEUKIN 10; T LYMPHOCYTE RECEPTOR;

ANTIGEN EXPRESSION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CANCER CELL; CELL PROLIFERATION; CELL STIMULATION; DOWN REGULATION; GENE EXPRESSION REGULATION; HUMAN; IMMUNE RESPONSE; LYMPHOCYTIC INFILTRATION; NONHUMAN; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION;

ANIMALS; ANTIGENS, CD5; AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-LYMPHOCYTES; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-10; NEOPLASMS; T-LYMPHOCYTES;

EID: 60649090236     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2008.11.007     Document Type: Review

References (40)

1. Reinherz E.L., Kung P.C., Golstein G., and Schlossman S.F. A monoclonal antibody with selective reactivity with functionally mature human thymocytes and all peripheral human T cells. J Immunol 123 (1979) 1312-1317
2. Boumsell L., Cippon H., Pham D., Raynal B., Lemerle J., Dausset J., et al. An antigen shared by a human T cell subset and B cell chronic lymphocytic leukemic cells. Distribution on normal and malignant lymphoid cells. J Exp Med 152 (1980) 229-234
3. Tarakhovsky A., Kanner S.B., Hombach J., Ledbetter J.A., Müller W., Kileen N., et al. A role for CD5 in TCR-mediated signal transduction and thymocyte selection. Science 269 (1995) 535-537
4. Bikah G., Carey J., Cialella J.R., Tarakhovsky A., and Bondada S. CD5-mediated negative regulation of antigen receptor-induced growth signals in B-1 B cells. Science 274 (1996) 1906-1909
5. Bismuth G., and Gary-Gouy H. Signaling functions of the CD5 molecule. Curr Trends Immunol 1 (1998) 79-87
6. Carsetti R., Rosado M.M., and Wardemann H. Peripheral development of B cells in mouse and man. Immunol Rev 197 (2004) 179-191
7. Antin J.H., Ault K.A., Rappeport J.M., and Smith B.R. B lymphocyte reconstitution after human bone marrow transplantation. Leu1 defines a distinct population of B lymphocytes. J Clin Invest 80 (1987) 325-332
8. Gary-Gouy H., et al. CD5 promotes B-cell survival through stimulation of autocrine IL-10 production. Blood 100 (2002) 4537-4543
9. Wortis H.H., Teutsch M., Higer M., Zheng J., and Parker D.C. B-cell activation by crosslinking of surface IgM or ligation of CD40 involves alternative signal pathways and results in different B-cell phenotypes. Proc Natl Acad Sci USA 92 (1995) 3348-3352
10. Gagro A., McCloskey N., Challa A., Holder M., Grafton G., Pound J.D., et al. CD5-positive and CD5-negative human B-cells converge to an indistinguishable population on signalling through B-cell receptors and CD40. Immunology 101 (2000) 201-209
11. Morikawa K., Oseko F., and Morikawa S. Induction of CD5 antigen on human CD5-B cells by stimulation with staphylococcus Aureus Cowan strain. Int Immunol 5 (1993) 809-816
12. Goodnow C.C. Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc Natl Acad Sci USA 93 (1996) 2264-2271
13. Stevenson F.K., and Caligaris-Cappio F. Chronic lymphocytic leukaemia: revelation from the B-cell receptor. Blood 103 (2004) 4389-4395
14. Caligaris Cappio F., Riva M., Tesio L., Schena M., Gaidano G., and Bergui L. Human normal CD5+ B lymphocytes can be induced to differentiate to CD5-B lymphocytes with germinal center features. Blood 73 (1989) 1259-1263
15. Defrance T., Vanbervliet B., Durand I., and Banchereau J. Human interleukin 4 down-regulates the surface expression of CD5 on normal and leukemic B cells. Eur J Immunol 19 (1989) 293-299
16. Freedman A.S., Freeman G., Whitman J., Segil J., Daley J., Levine H., et al. Expression and regulation of CD5 on in vitro activated human B cells. Eur J Immunol 19 (1989) 849-855
17. Siegrist CA. Neonatal and early life vaccinology. Vaccine. 19:3331-3346.
18. Sun C.M., Deriaud E., Leclerc C., and Lo-Man R. Upon TLR9 signaling, CD5+ B cells control the IL12-dependent Th1-priming capacity of neonatal DCs. Immunity 22 (2005) 467-477
19. Teutsch M., Higer M., Wang D., and Wortis H.W. Induction of CD5 on B and T cells is suppressed by cyclosporin A, FK-520 and rapamycin. Int Immunol 7 (1995) 381-392
20. Berland R., and Wortis H.H. An NFAT-dependent enhancer is necessary for anti-IgM-mediated induction of murine CD5 expression in primary splenic B cells. J Immunol 161 (1997) 277-285
21. Ceuppens J.L., and Baroja M.L. Monoclonal antibodies to the CD5 antigen can provide the necessary second signal for activation of isolated resting T cells by solid-phase-bound OKT3. J Immunol 137 (1986) 1816-1821
22. Ledbetter JA, Martin PJ, Wofsky D, Tsu TT, Beaty PG, Gladstone P. Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells. J Immunol. 135:2331-236.
23. Gary Gouy H., et al. In vivo association of CD5 with tyrosine-phosphorylated ZAP-70 and p21 phospho-zeta molecules in human CD3+ thymocytes. J Immunol 159 (1997) 3739-3747
24. Davies A.A., et al. CD5 is phosphorylated on tyrosine after stimulation of the T-cell antigen receptor complex. Proc Natl Acad Sci USA 89 (1992) 6368-6372
25. Simarro M., Pelassy C., Calvo J., Places L., Aussel C., and Lozano F. The cytoplasmic domain of CD5 mediates both TCR/CD3-dependent and -independent diacylglycerol production. J Immunol 159 (1997) 4307-4315
26. Lankester A.C., van Schijndel G.M.W., Cordell J.L., van Noessel C.J.M., and van Lier R.A.W. CD5 is associated with the human B cell antigen receptor complex. Eur J Immunol 24 (1994) 812-816
27. June C.H., Rabinovitch P.S., and Ledbetter J.A. CD5 antibodies increase intracellular ionized calcium concentration in T cells. J Immunol 138 (1987) 2782-2792
28. Gary-Gouy H., Bruhns P., Schmitt C., Dalloul A., Daeron M., and Bismuth G. The pseudo-immunoreceptor tyrosine-based activation motif of Cd5 mediates its inhibitory effect on B-cell Receptor signalling. J Biol Chem 275 (2000) 548-556
29. Gary-Gouy H., Harriague J., Dalloul A., Donnadieu E., and Bismuth G. CD5-negative regulation of B cell receptor signalling pathways originates from tyrosine residue Y429 outside an immunoreceptor tyrosine-based inhibitory motif. J Immunol 168 (2002) 232-239
30. Gary-Gouy H., Sainz-Perez A., Marteau J.B., Marfaing KOKA A., Delic J., Merle Beral H., et al. Natural phosphorylation of CD5 in chronic lymphocytic leukaemia B cells and analysis of CD5-regulated genes in a B cell line suggest a role for CD5 in malignant phenotype. J Immunol 179 (2007) 4335-4344
31. Berland R., and Wortis H.H. Origins and functions of B-1 cells with notes on the role of CD5. Annu Rev Immunol (2004) 253-299
32. Duan B., and Morel L. Role of B-1a cells in autoimmunity. Autoimmun Rev 5 (2006) 403-408
33. Hippen K.L., et al. CD5 maintains tolerance in anergic B cells. J Exp Med 191 (2000) 883-889
34. Bouaziz J.D., Yanaba K., and Tedder T.F. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev 224 (2008) 201-214
35. Fillatreau S., Sweenie C.H., McGeachy M.J., Gray D., and Anderton S.M. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 3 (2002) 944-950
36. Hawiger D., Masilamani R.F., Betelli E., Kuchroo V.K., and Nussenzweig M.C. Immunological unresponsiveness characterized by increased expression of CD5 on peripheral T cells induced by dendritic cells in vivo. Immunity 20 (2004) 695-705
37. Dorothée G., Vergnon I., ElHage F., Le Maux Chansac B., Ferrand V., Lécluse Y., et al. In situ sensory adaptation of tumor-infiltrating t lymphocytes to peptide-MHC levels elicits strong antitumor reactivity. J Immunol 174 (2005) 6888-6897
38. Azzam H.S., Grinberg A., Lui K., Shen H., Shores E.W., and Love P.E. CD5 expression is developmentally regulated by T cell receptor signals and TCR avidity. J Exp Med 188 (1998) 2301-2311
39. Lassam N., and Jay G. Suppression of MHC class I RNA in highly oncogenic cells occurs at the level of transcription initiation. J Immunol 143 (1989) 3792-3797
40. Freidlein G., ElHage F., Vergnon I., Richon C., SAulnier P., Lécluse Y., et al. Human CD5 protects circulating tumor antigen-specific CTL from tumor-mediated activation-induced cell death. J Immunol 178 (2007) 6821-6827